Expression of the growth factor pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta in the serum, cartilage and subchondral bone of patients with osteoarthritis

Joint Bone Spine

Volumn 80, Issue 4, 2013, Pages 407-413

  Kaspiris, Angelos ^a,b   Mikelis, Constantinos ^a,f   Heroult, Melanie ^c,g   Khaldi, Lubna ^d   Grivas, Theodoros B ^b,h   Kouvaras, Ioannis ^b   Dangas, Spyridon ^b   Vasiliadis, Elias ^b   Lioté, Frédéric ^e   Courty, José ^c   Papadimitriou, Evangelia ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b THRIASIO GENERAL HOSPITAL   (Greece)

^c Université Paris Est Creteil Val de Marne ^*  (France)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e CENTRE VIGGO PETERSEN   (France)

^f NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^g BAYER PHARMA AG   (Germany)

^h TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

Author keywords

Bone lining cells; Chondrocytes; Osteoarthritis; Osteocytes; Pleiotrophin; Protein tyrosine phosphatase

Indexed keywords

PLEIOTROPHIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE BETA; PROTEIN TYROSINE PHOSPHATASE ZETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARTILAGE; CARTILAGE CELL; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; OSTEOARTHRITIS; OSTEOCYTE; OSTEOPHYTE; PROTEIN EXPRESSION; SYNOVIAL FLUID; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; WESTERN BLOTTING;

EID: 84880328148     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.10.024     Document Type: Article

References (39)

1. Mapp P.I., Walsh D.A. Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis. Nat Rev Rheumatol 2012, 8:390-398.
2. Kwan Tat S., Lajeunesse D., Pelletier J.P., et al. Targeting subchondral bone for treating osteoarthritis: what is the evidence?. Best Pract Res Clin Rheumatol 2010, 24:51-70.
3. Pesesse L., Sanchez C., Henrotin Y. Osteochondral plate angiogenesis: a new treatment target in osteoarthritis. Joint Bone Spine 2011, 78:144-149.
4. Mikelis C., Koutsioumpa M., Papadimitriou E. Pleiotrophin as a possible new target for angiogenesis-related diseases and cancer. Recent Pat Anticancer Drug Discov 2007, 2:175-186.
5. Papadimitriou E., Mikelis C., Lampropoulou E., et al. Roles of pleiotrophin in tumor growth and angiogenesis. Eur Cytokine Netw 2009, 20:180-190.
6. Naeme P.J., Young C.N., Brock C.W., et al. Pleiotrophin is an abundant protein in dissociative extracts of bovine fetal epiphyseal cartilage and nasal cartilage from newborns. J Orthop Res 1993, 11:479-491.
7. Azizan A., Gaw J.U., Govindraj P., et al. Chondromodulin I and pleiotrophin gene expression in bovine cartilage and epiphysis. Matrix Biol 2000, 19:521-531.
8. Tare R.S., Oreffo R.O., Clarke N.M., et al. Pleiotrophin/osteoblast-stimulating factor -1: dissecting its diverse functions in bone formation. J Bone Miner Res 2002, 17:2009-2020.
9. Tare R.S., Oreffo R.O., Sato K., et al. Effects of targeted overexpression of pleiotrophin on postnatal bone development. Biochem Biophys Res Commun 2002, 298:324-332.
10. Pufe T., Bartscher M., Petersen W., et al. Expression of pleiotrophin, an embryonic growth, and differentiation factor in rheumatoid arthritis. Arthritis Rheum 2003, 48:660-667.
11. Pufe T., Bartscher M., Petersen W., et al. Pleiotrophin, an embryonic differentiation and growth factor, is expressed in osteoarthritis. Osteoarthritis Cartilage 2003, 11:260-264.
12. Pufe T., Groth G., Goldring M.B., et al. Effects of pleiotrophin, a heparin-binding growth factor, on human primary and immortalized chondrocytes. Osteoarthritis Cartilage 2007, 15:155-162.
13. Soulié P., Héroult M., Bernard I., et al. Immunoassay for measuring the heparin-binding growth factors HARP and MK in biological fluids. J Immunoassay Immunochem 2002, 23:33-48.
14. Schinke T., Gebauer M., Schilling A.F., et al. The protein tyrosine phosphatase RPTPz is expressed in differentiated osteoblasts and affects bone formation in mice. Bone 2008, 42:524-534.
15. Chen A.L., Fang C., Liu C., et al. Expression of bone morthogenetic proteins, receptors, and tissue inhibitors in human fetal, adult, and osteoarthritic articular cartilage. J Orthop Res 2004, 22:1188-1192.
16. Muehleman C., Bareither D., Huch K., et al. Prevalence of degenerative morphological changes in the joints of the lower extremity. Osteoarthritis Cartilage 1997, 5:23-37.
17. Jansen H., Meffert R.H., Birkenfeld F., et al. Detection of vascular endothelial growth factor (VEGF) in moderate osteoarthritis in a rabbit model. Ann Anat 2012, 194:452-456.
18. Yamairi F., Utsumi H., Ono Y., et al. Expression of vascular endothelial growth factor (VEGF) associated with histopathological changes in rodent models of osteoarthritis. J Toxicol Pathol 2011, 24:137-142.
19. Enomoto H., Inoki I., Komiya K., et al. Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. Am J Pathol 2003, 162:171-181.
20. Zamli Z., Sharif M. Chondrocyte apoptosis: a cause or consequence of osteoarthritis?. Int J Rheum Dis 2011, 14:159-166.
21. Bowden E.T., Stoica G.E., Wellstein A. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 2002, 277:35862-35868.
22. Zhang N., Yeh H.J., Zhong R., et al. A dominant-negative pleiotrophin mutant introduced by homologous recombination leads to germ-cell apoptosis in male mice. Proc Natl Acad Sci U S A 1999, 96:6734-6738.
23. Soh B.S., Song C.M., Vallier L., et al. Pleiotrophin enhances clonal growth and long-term expansion of human embryonic stem cells. Stem Cells 2007, 25:3029-3037.
24. Tsirmoula S., Dimas K., Hatziapostolou M., et al. Implication of pleiotrophin in human PC3 prostate cancer cell growth in vivo. Cancer Sci 2012, 103:1826-1832.
25. Park T.J., Jeong B.R., Tateno C., et al. Pleiotrophin inhibits transforming growth factor beta1-induced apoptosis in hepatoma cell lines. Mol Carcinog 2008, 47:784-796.
26. Li J., Wei H., Chesley A., et al. The pro-angiogenic cytokine pleiotrophin potentiates cardiomyocyte apoptosis through inhibition of endogenous AKT/PKB activity. J Biol Chem 2007, 282:34984-34993.
27. Lu K.V., Jong K.A., Kim G.Y., et al. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem 2005, 280:26953-26964.
28. Mikelis C., Sfaelou E., Koutsioumpa M., et al. Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta. FASEB J 2009, 23:1459-1469.
29. Imai S., Heino T.J., Hienola A., et al. Osteocyte-derived HB-GAM (pleiotrophin) is associated with bone formation and mechanical loading. Bone 2009, 44:785-794.
30. Petersen W., Wildemann B., Pufe T., et al. The angiogenic peptide pleiotrophin (PTN/HB-GAM) is expressed in fracture healing: an immunohistochemical study in rats. Arch Orthop Trauma Surg 2004, 124:603-607.
31. Li G., Bunn J.R., Mushipe M.T., et al. Effects of pleiotrophin (PTN) overexpression on mouse long bone development, fracture healing and bone repair. Calcif Tissue Int 2005, 76:299-306.
32. Yang X., Tare R.S., Partridge K.A., et al. Induction of human osteoprogenitor chemotaxis, proliferation, differentiation, and bone formation by osteoblast stimulating factor-1/pleiotrophin: osteoconductive biomimetic scaffolds for tissue engineering. J Bone Miner Res 2003, 18:47-57.
33. Papadimitriou E., Heroult M., Courty J., et al. Endothelial cell proliferation induced by HARP: implication of N or C terminal peptides. Biochem Biophys Res Commun 2000, 274:242-248.
34. Petersen W., Rafii M. Immunolocalization of the angiogenetic factor pleiotrophin (PTN) in the growth plate of mice. Arch Orthop Trauma Surg 2001, 121:414-416.
35. Johnson W.E., Patterson A.M., Eisenstein S.M., et al. The presence of pleiotrophin in the human intervertebral disc is associated with increased vascularization: an immunohistologic study. Spine 2007, 32:1295-1302.
36. Vacherot F., Delbé J., Heroult M., et al. Glycosaminoglycans differentially bind HARP and modulate its biological activity. J Biol Chem 1999, 274:7741-7747.
37. Jaiprakash A., Prasadam I., Feng J.Q., et al. Phenotypic characterization of osteoarthritic osteocytes from the sclerotic zones: a possible pathological role in subchonral bone sclerosis. Int J Biol Sci 2012, 8:406-417.
38. Everts V., Delaisse J.M., Kopper W., et al. The bone-lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 2002, 17:77-90.
39. Koutsioumpa M., Hatziapostolou M., Mikelis C., et al. Aprotinin stimulates angiogenesis and human endothelial cell migration through the growth factor pleiotrophin and its receptor protein tyrosine phosphatise beta/zeta. Eur J Pharmacol 2009, 602:245-249.